C12N 2770/32211
Cardiovirus
Official title: Cardiovirus, e.g. encephalomyocarditis virus
C12N2770/32211 (Cardiovirus) appears on 15 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 24
- Assignees
- 19
- Inventors
- 74
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 3 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 4 |
| 2015 | 0 | 1 |
| 2016 | 2 | 0 |
| 2017 | 1 | 5 |
| 2018 | 3 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
- C12N 2770/32234Use of virus or viral component as vaccineIndexing code7
- C12N 2770/32261Methods of inactivation or attenuationIndexing code5
- C12N 2770/32222New viral proteins or individual genes, new structural or functional aspects ofIndexing code4
- C12N 2770/32241Use of virus, viral particle or viral elements as a vectorIndexing code3
- C12N 2770/32232Use of virus as therapeutic agent, other than vaccineIndexing code2
- C12N 2770/32271Demonstrated in vivo effectIndexing code1
- C12N 2770/32221Viruses as suchIndexing code0
- C12N 2770/32223Virus like particles [vlp]Indexing code0
All 12 subgroupsShow fewer
Recent patents
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin9 Apr 2024US 11,952,603 B2Scientific Protein Laboratories, LLC
- Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin9 Oct 2018US 10,093,916 B2Scientific Protein Laboratories, LLC
- RNA interference functions as an antiviral immunity in mammals31 Jul 2018US 10,034,929 B2The Regents of the University of California
- Methods and materials for reducing the severity of viral infections29 May 2018US 9,981,019 B2Mayo Foundation for Medical Education and Research
- Systems and methods for protein expression2 May 2024US 2024/0141373 A1Excepgen Inc.
- Encapsulated rna replicons and methods of use28 Dec 2023US 2023/0416308 A1Oncorus, Inc.
- Systems and methods for protein expression23 Feb 2023US 2023/0056404 A1
- Systems and methods for protein expression29 Sep 2022US 2022/0307037 A1Excepgen Inc.
- Pharmaceutical composition containing stabilized nucleic acid adjuvant28 Jul 2022US 2022/0233700 A1Korea Institute of Science and Technology
Most cited
By later US patents
- Drug delivery product and methods22US 7,740,861 B2University of Massachusetts · 2010
- Rapid, versatile and simple system for expressing genes in eukaryotic cells21US 5,135,855 AThe United States of America as represented by the Department of Health and Human Services · 1992
- Encephalomyocarditis virus vaccine10US 5,213,795 AOxford · 1993
- Drug delivery product and methods8US 8,580,275 B2University of Massachusetts · 2013
- Isoflavone anti-viral compounds4US 9,408,826 B2Kineta, Inc. · 2016